Outset Medical (OM) EBIT (2019 - 2026)

Outset Medical (OM) has 8 years of EBIT data on file, last reported at -$16.9 million in Q1 2026.

• On a quarterly basis, EBIT fell 3.17% year-over-year to -$16.9 million in Q1 2026; TTM through Mar 2026 was -$67.2 million, a 27.61% increase from a year earlier, with the FY2025 full-year figure at -$66.7 million, up 41.16% from the prior year.
• EBIT for Q1 2026 stood at -$16.9 million, up from -$17.6 million in the prior quarter.
• Over the last five years, EBIT for OM reached as high as -$15.8 million in Q3 2025 and fell as low as -$45.5 million in Q3 2023.
• Historically, EBIT has averaged -$31.0 million across 5 years, with a median of -$36.5 million in 2022.
• Across the five-year window, EBIT slumped 46.19% in 2022 and jumped 55.57% in 2025, its largest moves.
• Year by year, EBIT stood at -$39.8 million in 2022, then advanced by 6.2% to -$37.4 million in 2023, then surged by 41.48% to -$21.9 million in 2024, then advanced by 19.35% to -$17.6 million in 2025, then grew by 4.03% to -$16.9 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$16.9 million in Q1 2026, -$17.6 million in Q4 2025, and -$15.8 million in Q3 2025.